Geriatric Medicines Market Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2018 - 2026

Nov 2018| TMR392B| Transparency

Report Highlights

Global Geriatric Medicines Market: Overview

This report on the global geriatric medicines market analyzes the current and future prospects of the market. The report comprises a comprehensive executive summary, including a market snapshot that provides overall information of various segments. The research is a combination of primary and secondary research. Primary research formed the bulk of our research efforts along with information collected from telephonic interviews and interactions via e-mails. Secondary research involved study of company websites, annual reports, press releases, stock analysis presentations, and various international and national databases. The report provides market value in terms of US$ Mn for each segment for the period from 2016 to 2026, considering the macro and micro environmental factors. Growth rates for each segment within the global geriatric medicines market have been determined after a thorough analysis of past trends, demographics, future trends, technological developments, and regulatory requirements.

A detailed qualitative analysis of factors responsible for driving and restraining expansion of the market and future opportunities has been provided in the market overview section. The report also provides insights into the key trends of the geriatric medicines market. The report includes market attractiveness analysis of the major geographic regions that provides a thorough analysis of the overall competitive scenario in the global geriatric medicines market.

Market value in terms of US$ Mn for the period between 2016 and 2026 along with the compound annual growth rate (CAGR %) from 2018 to 2026 are provided for all the segments, considering 2017 as the base year. The year-on-year growth of the global geriatric medicines market for each segment is also reflected. Additionally, market-related factors such as growing geriatric population, favorable government policies for elderly and developing healthcare infrastructure in emerging countries and historical year-on-year growth have been taken into consideration while estimating the market size.

Global Geriatric Medicines Market: Key Segments

The global geriatric medicines market has been segmented based on therapeutic category, condition, distribution channel, and region. In terms of therapeutic category, the geriatric medicine market has been divided into analgesic, antihypertensive, statins, antidiabetic, proton pump inhibitor, anticoagulant, antipsychotic & antidepressant, and others. In terms of condition, the market has been segregated into cardiovascular, arthritis, neurological, cancer, osteoporosis, respiratory, and others. In terms of distribution channel, the market has been classified into hospital pharmacies, retail pharmacies, and online pharmacies.

Global Geriatric Medicines Market: Regional Outlook

In terms of region, the global geriatric medicines market has been categorized into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. Additionally, the regions have been further segmented into major countries in each of the regions. These include the U.S., Canada, the U.K., Germany, France, Italy, Spain, China, Australia & New Zealand, Japan, India, Brazil, GCC, South Africa, and Mexico.

Companies Mentioned in Report

The report also profiles major players in the geriatric medicines market based on various attributes such as company overview, financial overview, SWOT analysis, key business strategies, product portfolio, and recent developments. Key companies profiled in the report include Pfizer, Inc., Merck & Co., Inc., AstraZeneca, Bristol-Myers Squibb Company, Novartis AG, Sanofi S.A., GlaxoSmithKline plc, Eli Lilly and Company, Abbott Laboratories, and Boehringer Ingelheim GmbH.

 

The global geriatric medicines market has been segmented as follows:

Global Geriatric Medicines Market, by Therapeutic Category

Analgesic
Antihypertensive
Statins
Antidiabetic
Proton Pump Inhibitor
Anticoagulant
Antipsychotic and Antidepressant
Others
Global Geriatric Medicines Market, by Condition

Cardiovascular
Arthritis
Diabetes
Neurological
Cancer
Osteoporosis
Respiratory
Others
Global Geriatric Medicines Market, by Distribution Channel

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Global Geriatric Medicines Market, by Region

North America
U.S.
Canada
Europe
Germany
U.K.
France
Spain
Italy
Rest of Europe
Asia Pacific
Australia & New Zealand
Japan
China
India
Rest of Asia Pacific
Latin America
Brazil
Mexico
Rest of Latin America
Middle East & Africa
GCC
South Africa
Rest of Middle East & Africa

  • Table 1 : Major Causes of Death for Persons Aged 65 or Over, 2014 (Standardized Death Rates per 100,000 Inhabitants)
  • Table 2 : Healthcare Overview (2016 or latest available)
  • Table 3 : Global Geriatric Medicines Market Value (US$ Mn) Forecast, by Therapeutic Category, 2016–2026
  • Table 4 : Global Geriatric Medicines Market Value (US$ Mn) Forecast, by Condition, 2016–2026
  • Table 5 : Global Geriatric Medicines Market Value (US$ Mn) Forecast, by Distribution Channel, 2016–2026
  • Table 6 : Global Geriatric Medicines Market Value (US$ Mn) Forecast, by Region, 2016–2026
  • Table 7 : North America Geriatric Medicines Market Value (US$ Mn) Forecast, by Therapeutic Category, 2018–2026
  • Table 8 : North America Geriatric Medicines Market Value (US$ Mn) Forecast, by Condition, 2018–2026
  • Table 9 : North America Geriatric Medicines Market Value (US$ Mn) Forecast, by Distribution Channel, 2016–2026
  • Table 10 : North America Geriatric Medicines Market Value (US$ Mn) Forecast, by Country, 2016–2026
  • Table 11 : Europe Geriatric Medicines Market Value (US$ Mn) Forecast, by Therapeutic Category, 2018–2026
  • Table 12 : Europe Geriatric Medicines Market Value (US$ Mn) Forecast, by Condition, 2018–2026
  • Table 13 : Europe Geriatric Medicines Market Value (US$ Mn) Forecast, by Distribution Channel, 2016–2026
  • Table 14 : Europe Geriatric Medicines Market Value (US$ Mn) Forecast, by Country/Sub-region, 2016–2026
  • Table 15 : Asia Pacific Geriatric Medicines Market Value (US$ Mn) Forecast, by Therapeutic Category, 2018–2026
  • Table 16 : Asia Pacific Geriatric Medicines Market Value (US$ Mn) Forecast, by Condition, 2018–2026
  • Table 17 : Asia Pacific Geriatric Medicines Market Value (US$ Mn) Forecast, by Distribution Channel, 2016–2026
  • Table 18 : Asia Pacific Geriatric Medicines Market Value (US$ Mn) Forecast, by Country/Sub-region, 2016–2026
  • Table 19 : Latin America Geriatric Medicines Market Value (US$ Mn) Forecast, by Therapeutic Category, 2018–2026
  • Table 20 : Latin America Geriatric Medicines Market Value (US$ Mn) Forecast, by Condition, 2018–2026
  • Table 21 : Latin America Geriatric Medicines Market Value (US$ Mn) Forecast, by Distribution Channel, 2016–2026
  • Table 22 : Latin America Geriatric Medicines Market Value (US$ Mn) Forecast, by Country/Sub-region, 2016–2026
  • Table 23 : Middle East & Africa Geriatric Medicines Market Value (US$ Mn) Forecast, by Therapeutic Category, 2018–2026
  • Table 24 : Middle East & Africa Geriatric Medicines Market Value (US$ Mn) Forecast, by Condition, 2018–2026
  • Table 25 : Middle East & Africa Geriatric Medicines Market Value (US$ Mn) Forecast, by Distribution Channel, 2016–2026
  • Table 26 : Middle East & Africa Geriatric Medicines Market Value (US$ Mn) Forecast, by Country/Sub-region, 2016–2026
  • Figure 1 : Global Geriatric Medicines Market Snapshot
  • Figure 2 : Global Geriatric Medicines Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2016–2026
  • Figure 3 : Global Geriatric Medicines Market Value Share by Therapeutic Category (2017)
  • Figure 4 : Global Geriatric Medicines Market Value Share by Condition (2017)
  • Figure 5 : Global Geriatric Medicines Market Value Share by Distribution Channel (2017)
  • Figure 6 : Global Geriatric Medicines Market Value Share by Region (2017)
  • Figure 7 : Global Geriatric Medicines Market Value Share, by Therapeutic Category, 2017 and 2026
  • Figure 8 : Global Geriatric Medicines Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2016–2026, by Analgesics
  • Figure 9 : Global Geriatric Medicines Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2016–2026, by Antihypertensive
  • Figure 10 : Global Geriatric Medicines Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2016–2026, by Statins
  • Figure 11 : Global Geriatric Medicines Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2016–2026, by Antidiabetic
  • Figure 12 : Global Geriatric Medicines Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2016–2026, by Proton Pump Inhibitor
  • Figure 13 : Global Geriatric Medicines Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2016–2026, by Anticoagulant
  • Figure 14 : Global Geriatric Medicines Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2016–2026, by Antipsychotic and Antidepressant
  • Figure 15 : Global Geriatric Medicines Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2016–2026, by Others
  • Figure 16 : Global Geriatric Medicines Market Value Share, by Condition, 2017 and 2026
  • Figure 17 : Global Geriatric Medicines Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2016–2026, by Cardiovascular
  • Figure 18 : Global Geriatric Medicines Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2016–2026, by Arthritis
  • Figure 19 : Global Geriatric Medicines Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2016–2026, by Diabetes
  • Figure 20 : Global Geriatric Medicines Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2016–2026, by Neurological
  • Figure 21 : Global Geriatric Medicines Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2016–2026, by Cancer
  • Figure 22 : Global Geriatric Medicines Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2016–2026, by Osteoporosis
  • Figure 23 : Global Geriatric Medicines Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2016–2026, by Antipsychotic and Antidepressant
  • Figure 24 : Global Geriatric Medicines Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2016–2026, by Others
  • Figure 25 : Global Geriatric Medicines Market Value Share Analysis, by Distribution Channel, 2017 and 2026
  • Figure 26 : Global Geriatric Medicines Market Value (US$ Mn) and Y-o-Y Growth (%), by Hospital Pharmacies, 2016–2026
  • Figure 27 : Global Geriatric Medicines Market Value (US$ Mn) and Y-o-Y Growth (%), by Retail Pharmacies, 2016–2026
  • Figure 28 : Global Geriatric Medicines Market Value (US$ Mn) and Y-o-Y Growth (%), by Online Pharmacies, 2016–2026
  • Figure 29 : Global Geriatric Medicines Market Value Share, by Region, 2017 and 2026
  • Figure 30 : North America Geriatric Medicines Market Value (US$ Mn) Forecast, 2016–2026
  • Figure 31 : North America Geriatric Medicines Market Attractiveness Analysis, by Country
  • Figure 32 : North America Geriatric Medicines Market Value Share Analysis, by Therapeutic Category, 2017 and 2026
  • Figure 33 : North America Geriatric Medicines Market Value Share Analysis, by Condition, 2017 and 2026
  • Figure 34 : North America Geriatric Medicines Market Value Share Analysis, by Distribution Channel, 2017 and 2026
  • Figure 35 : North America Geriatric Medicines Market Value Share Analysis, by Country, 2017 and 2026
  • Figure 36 : Europe Geriatric Medicines Market Value (US$ Mn) Forecast, 2016–2026
  • Figure 37 : Europe Geriatric Medicines Market Attractiveness Analysis, by Country/Sub-region
  • Figure 38 : Europe Geriatric Medicines Market Value Share Analysis, by Therapeutic Category, 2017 and 2026
  • Figure 39 : Europe Geriatric Medicines Market Value Share Analysis, by Condition, 2017 and 2026
  • Figure 40 : Europe Geriatric Medicines Market Value Share Analysis, by Distribution Channel, 2017 and 2026
  • Figure 41 : Europe Geriatric Medicines Market Value Share Analysis, by Country/Sub-region, 2017 and 2026
  • Figure 42 : Asia Pacific Geriatric Medicines Market Value (US$ Mn) Forecast, 2016–2026
  • Figure 43 : Asia Pacific Geriatric Medicines Market Attractiveness Analysis, by Country/Sub-region
  • Figure 44 : Asia Pacific Geriatric Medicines Market Value Share Analysis, by Therapeutic Category, 2017 and 2026
  • Figure 45 : Asia Pacific Geriatric Medicines Market Value Share Analysis, by Condition, 2017 and 2026
  • Figure 46 : Asia Pacific Geriatric Medicines Market Value Share Analysis, by Distribution Channel, 2017 and 2026
  • Figure 47 : Asia Pacific Geriatric Medicines Market Value Share Analysis, by Country/Sub-region, 2017 and 2026
  • Figure 48 : Latin America Geriatric Medicines Market Value (US$ Mn) Forecast, 2016–2026
  • Figure 49 : Latin America Geriatric Medicines Market Attractiveness Analysis, by Country/Sub-region
  • Figure 50 : Latin America Geriatric Medicines Market Value Share Analysis, by Therapeutic Category, 2017 and 2026
  • Figure 51 : Latin America Geriatric Medicines Market Value Share Analysis, by Condition, 2017 and 2026
  • Figure 52 : Latin America Geriatric Medicines Market Value Share Analysis, by Distribution Channel, 2017 and 2026
  • Figure 53 : Latin America Geriatric Medicines Market Value Share Analysis, by Country/Sub-region, 2017 and 2026
  • Figure 54 : Middle East & Africa (MEA) Geriatric Medicines Market Value (US$ Mn) Forecast, 2016–2026
  • Figure 55 : Middle East & Africa (MEA) Geriatric Medicines Market Attractiveness Analysis, by Country/Sub-region
  • Figure 56 : Middle East & Africa (MEA) Geriatric Medicines Market Value Share Analysis, by Therapeutic Category, 2017 and 2026
  • Figure 57 : Middle East & Africa (MEA) Geriatric Medicines Market Value Share Analysis, by Condition, 2017 and 2026
  • Figure 58 : Middle East & Africa (MEA) Geriatric Medicines Market Value Share Analysis, by Distribution Channel, 2017 and 2026
  • Figure 59 : Middle East & Africa (MEA) Geriatric Medicines Market Value Share Analysis, by Country/Sub-region, 2017 and 2026
  • Figure 60 : Pfizer, Inc. Revenue (US$ Bn) and Y-o-Y Growth (%), 2014–2017
  • Figure 61 : Pfizer, Inc. R&D Intensity (%) - Company Level or Segment Level, 2015–2017
  • Figure 62 : Pfizer, Inc. Breakdown of Net Sales, by Region, 2017
  • Figure 63 : Merck & Co., Inc. Revenue (US$ Bn) and Y-o-Y Growth (%), 2014–2017
  • Figure 64 : Merck & Co., Inc. R&D Intensity (%) - Company Level or Segment Level, 2014–2017
  • Figure 65 : Merck & Co., Inc. Break-up of Net Sales, by Region, 2017
  • Figure 66 : AstraZeneca Revenue (US$ Bn) and Y-o-Y Growth (%), 2014–2017
  • Figure 67 : AstraZeneca Breakdown of Net Sales, by Region, 2017
  • Figure 68 : AstraZeneca Marketing & Sales and R&D Expenses, 2015–2017
  • Figure 69 : Bristol-Myers Squibb Company Revenue (US$ Bn) and Y-o-Y Growth (%), 2014–2017
  • Figure 70 : Bristol-Myers Squibb Company R&D Intensity (%) - Company Level or Segment Level, 2015–2017
  • Figure 71 : Bristol-Myers Squibb Company Breakdown of Net Sales, by Region, 2017
  • Figure 72 : Novartis AG Revenue (US$ Bn) and Y-o-Y Growth (%), 2014–2017
  • Figure 73 : Novartis AG Marketing & Sales and R&D Expenses, 2016–2017
  • Figure 74 : Novartis AG Breakdown of Net Sales, by Business Segment, 2017
  • Figure 75 : Novartis AG Breakdown of Net Sales, by Region, 2017
  • Figure 76 : Sanofi S.A. Breakdown of Net Sales, by Region, 2017
  • Figure 77 : Sanofi S.A. Revenue (US$ Bn) and Y-o-Y Growth (%), 2014–2017
  • Figure 78 : Sanofi S.A. Breakdown of Net Sales, by Business Segment, 2017
  • Figure 79 : Sanofi S.A. R&D Intensity and Sales & Marketing Intensity (Pharmaceutical Segment) - Company Level, 2015–2017
  • Figure 80 : GlaxoSmithKline plc Revenue (US$ Bn) and Y-o-Y Growth (%), 2014–2017
  • Figure 81 : GlaxoSmithKline plc Marketing & Sales and R&D Expenses, 2015–2017
  • Figure 82 : GlaxoSmithKline plc Breakdown of Net Sales, by Business Segment, 2017
  • Figure 83 : GlaxoSmithKline plc Breakdown of Net Sales, by Region, 2017
  • Figure 84 : Eli Lilly and Company Revenue (US$ Mn) and Y-o-Y Growth (%), 2014–2017
  • Figure 85 : Eli Lilly and Company R&D Intensity (%) - Company Level or Segment Level, 2015–2017
  • Figure 86 : Eli Lilly and Company Breakdown of Net Sales, by Region, 2017
  • Figure 87 : Abbott Laboratories, Revenue (US$ Mn) and Y-o-Y Growth (%), 2015–2017
  • Figure 88 : Abbott Laboratories, Breakdown of Net Sales, by Business Segment, 2017
  • Figure 89 : Abbott Laboratories, Breakdown of Net Sales, by Region 2017
  • Figure 90 : Boehringer Ingelheim GmbH, Revenue (US$ Mn) and Y-o-Y Growth (%), 2014–2017
  • Figure 91 : Boehringer Ingelheim GmbH, Breakdown of Net Sales, by Business Segment, 2017
  • Figure 92 : Boehringer Ingelheim GmbH, Breakdown of Net Sales, by Region 2017
  • Figure 93 : Boehringer Ingelheim GmbH, R&D (US$ Mn) and Y-o-Y Growth (%), 2014–2017

Leaders in analytics, research and advisory services for Fortune 500 companies, scores of high potential startups, and financial institutions. Our success stories have proven why we are a prominent provider of a cutting-edge syndicated and customized research services. Leverage the best of our seasoned research analysts who had a keen interest and enviable expertise of almost 4 million hours in global, regional, and local market intelligence.

Why BCC Research?

Every purchase provides access to:

  • Thousands of recently published reports from select publishers
  • Member Discounts of up to 50% on over 20,000 additional reports from all publishers
  • Our analysts and research concierge for all inquiries
CUSTOM RESEARCH

Need a custom data table, graph or complete report? Tell us more.

Contact Us
Share This Report